Imatinib Mesylate Tablet
Product Images NDC 67184-0533

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 67184-0533). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Imt 03)

A Kaplan-Meier survival curve comparing Imatinib 400 mg to placebo. The y-axis represents the probability of being alive and recurrence-free, while the x-axis represents survival time in months up to 108. Censored data points are marked for both groups. The graph includes the number of patients at risk over time for each group.*

FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Imt 04)

A Kaplan-Meier survival curve chart depicting the probability of recurrence-free survival over time in months for two groups treated with imatinib for 12 months and 36 months. The chart includes a legend, statistical values (p-value, hazard ratio with confidence interval), censored observations, and numbers at risk with event counts below the x-axis.*

FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Imt 05)

A Kaplan-Meier survival curve depicting the probability of overall survival over time (in months) comparing two groups treated with imatinib mesylate. The graph shows survival probabilities for 12 months and 36 months treatment groups, including censored observations and an inset with event counts, hazard ratio, confidence intervals, and P-value.*

FDA Label Image

Principal Display Panel – Bottle Label – 100 mg Tablets Ndc 0078-0401-34 Imatinib Mesylate Tablets® (imatinib Mesylate) Tablets 100 mg Rx Only Each Tablet Contains 100 mg Of Imatinib Free Base. 90 Tablets (Imt 100mg 500s Label)

Imatinib Mesylate Tablets 100 mg oral tablets packaging label from Qilu Pharmaceutical Co., Ltd. The label states the package contains 500 tablets, includes storage instructions, and lists the manufacturer as Qilu Pharmaceutical (Hainan) Co., Ltd. with a revision date of 11/2021.*

FDA Label Image

Principal Display Panel – Bottle Label – 100 mg Tablets Ndc 0078-0401-34 Imatinib Mesylate Tablets® (imatinib Mesylate) Tablets 100 mg Rx Only Each Tablet Contains 100 mg Of Imatinib Free Base. 90 Tablets (Imt 100mg 90s Label)

Imatinib Mesylate Tablets 100 mg oral tablets label showing a package of 90 tablets by Qilu Pharmaceutical Co., Ltd. The label states prescription use only, contains 100 mg imatinib free base per tablet, storage instructions, and manufacturer information from Haikou, China, with a QR code and barcode present.*

FDA Label Image

Principal Display Panel – Aluminum Foil Label – 100 mg Tablets (Imt 100mg Blister)

A packaging label for imatinib mesylate tablets, 100 mg strength, manufactured by Qilu Pharmaceutical Co., Ltd in China. The label includes multiple repeated sections each displaying the product name, strength, and placeholders for lot number and expiration date, along with barcodes under each section. The label revision date is 10/2021.*

FDA Label Image

Principal Display Panel – Carton Label – 100 mg Tablets (Imt 100mg Carton)

Imatinib Mesylate Tablets 100 mg oral tablets packaging label by Qilu Pharmaceutical Co., Ltd. The label indicates each tablet contains 100 mg of imatinib free base, with a total count of 30 tablets (3 cards of 10 tablets). The package is not child resistant and is for institutional use only. The label also displays the NDC 67184-0532-3 and includes storage and manufacturing details, along with a barcode.*

FDA Label Image

Principal Display Panel – Bottle Label – 400 mg Tablets (Imt 400mg 300s Label)

Imatinib Mesylate Tablets 400 mg oral tablet label for a 300-tablet bottle, manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd. The label includes storage instructions, dosage reference, a barcode, and regulatory information including lot and expiration placeholders.*

FDA Label Image

Principal Display Panel – Bottle Label – 400 mg Tablets (Imt 400mg 30s Label)

Imatinib Mesylate Tablets 400 mg oral tablets label showing a package containing 30 tablets. The label includes storage instructions, manufacturer Qilu Pharmaceutical Co., Ltd. (Hainan), China, and dosage information, with a 400 mg strength prominently displayed. The label has an NDC of 67184-0533-1 and barcodes.*

FDA Label Image

Principal Display Panel – Aluminum Foil Label – 400 mg Tablets (Imt 400mg Blister)

Blister packaging label for Imatinib Mesylate Tablet 400 mg, manufactured by Qilu Pharmaceutical Co., Ltd. Each tablet is marked with the dosage strength in blue and includes placeholders for lot number and expiration date information. The label displays a barcode and states the product is made in China.*

FDA Label Image

Principal Display Panel – Carton Label – 400 mg Tablets (imatinib Mesylate) Tablets 400 mg Per Tablet Each Tablet Contains 400 mg Of Imatinib Free Base 30 Tablets Rx Only Novartis (Imt 400mg Carton)

Imatinib Mesylate Tablets 400 mg oral tablets packaging label from Qilu Pharmaceutical Co., Ltd. The label states each tablet contains 400 mg of imatinib free base and includes a 30 tablet count (3 cards of 10 tablets). The packaging has dosage strength in blue boxes and includes institutional use and storage warnings, alongside a barcode and NDC number 67184-0533-3.*

FDA Label Image

Figure 1 Progression Free Survival (itt Principle) (Imt Figure01 Free Survival)

A line graph depicting percentage without progression over months since randomization, comparing two treatment arms: Imatinib Mesylate and IFN+Ara-C. The graph shows a higher progression-free percentage over time for the Imatinib Mesylate group versus the IFN+Ara-C group, with supporting statistics including number of patients, hazard ratio, and log-rank test p-value.*

FDA Label Image

Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Imt Figure02 Time To Progression)

A Kaplan-Meier survival curve showing the percentage of patients without progression to AP or BC over time in months since randomization. The graph compares two groups: Imatinib Mesylate arm and IFN+Ara-C arm, with accompanying patient numbers, hazard ratio, confidence interval, and significance test results.*

FDA Label Image

Imatinib Structural Formula (Imt Structure Formula)

Chemical structure of imatinib mesylate, showing its molecular framework with multiple aromatic rings and functional groups as commonly depicted in pharmaceutical chemistry.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.